Rory Shallis, MD

2026

• Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study

  Badar T, Foran J, Jamy O, Lin C, Patel A, Wang Y, Kumar M, Shallis R, Diebold K, Coltoff A, Goldberg A, Bewersdorf J, Zabel K, Foucar C, Abaza Y, Murthy G, Palmisiano N, DuVall A, Kota V, Patel S, Zeidan A, Murthy H, Kharfan-Dabaja M, Atallah E, Litzow M. Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study. Leukemia 2026, 1-9. PMID: 42675141, DOI: 10.1038/s41375-026-03119-6.

  Peer-Reviewed Original Research

  Altmetric

• Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

  Rolles B, Bewersdorf J, Kewan T, Blaha O, Stempel J, Al Ali N, DeZern A, Sekeres M, Uy G, Urrutia S, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Barua S, Chandhok N, Logothetis C, Bidikian A, Getz T, Roboz G, Wang E, Harris A, Amaya M, Hawkins H, Ball S, Grenet J, Abedi P, Shimony S, Lindsley R, Xie Z, Madanat Y, Abaza Y, Badar T, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Al‐Rabi K, Halahleh K, Hiwase D, Diez‐Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al‐Kali A, Ogawa S, Nannya Y, Della Porta M, Komrokji R, Zeidan A, Stahl M. Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS). American Journal Of Hematology 2026 PMID: 42657925, DOI: 10.1002/ajh.70474.

  Peer-Reviewed Original Research

  Altmetric

• The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

  Shallis R, VanOudenhove J, Chandhok N, Watts J, Jeyakumar D, Reed D, Bewersdorf J, Durecki D, Boerner S, Little R, Gore S, Li J, Bao X, Chen L, Ghatak S, Prebet T, Bindra R, Zeidan A, Halene S. The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes. British Journal Of Haematology 2026 PMID: 42644317, DOI: 10.1111/bjh.70756.

  Peer-Reviewed Original Research

• Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

  Bewersdorf J, Kewan T, Wei W, Rudra Gupta T, Stempel J, Al Ali N, DeZern A, Sekeres M, Uy G, Urrutia S, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Hawkins H, Chandhok N, Logothetis C, Bidikian A, Getz T, Roboz G, Rolles B, Wang E, Harris A, Amaya M, Ball S, Grenet J, Xie Z, Madanat Y, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta M, Komrokji R, Zeidan A. Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database. Blood Cancer Journal 2026, 16: 155. PMID: 42373605, PMCID: PMC13575243, DOI: 10.1038/s41408-026-01543-6.

  Peer-Reviewed Original Research

  This study investigates the impact of combining hypomethylating agents with venetoclax for high-risk myelodysplastic syndromes, finding increased remission rates but no significant overall survival benefit.

  Full Summary

• Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax A Multicenter Cohort Study

  Filimon S, Ghamari A, Vakilpour A, Patel R, Achar R, Akhter N, Shallis R, DeCara J, Altman J, Smith A, Matthews A, Lai C, Brunner A, Farina K, Gilman H, Neilan T, Upadhyay D, Chittams J, Anazco F, Patel A, Tremblay D, Scherrer-Crosbie M. Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax A Multicenter Cohort Study. JACC Advances 2026, 5: 102821. PMID: 42312783, PMCID: PMC13308248, DOI: 10.1016/j.jacadv.2026.102821.

  Peer-Reviewed Original Research

  Altmetric

• NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

  Pollyea D, Altman J, Assi R, Bachiashvili K, Bhatt V, Fathi A, Fedorov K, Foran J, Gojo I, Goldberg A, Hall A, Jonas B, Levine M, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival M, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone R, Thota S, Uy G, Walker A, Wang E, Awotiwon A, Roth S, Stehman K. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. Journal Of The National Comprehensive Cancer Network 2026, 24: 222-229. PMID: 42297017, DOI: 10.6004/jnccn.2026.0028.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Altmetric

  MeSH Keywords

• Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia

  Ito S, Potnis K, Ng D, Patel K, Sra M, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. Blood Red Cells & Iron 2026, 2: 100076. PMID: 42077391, PMCID: PMC13134686, DOI: 10.1016/j.brci.2026.100076.

  Peer-Reviewed Original Research

  This study investigates how trainee-led teams developed updated consensus guidelines for managing peritoneal surface malignancies, demonstrating effective collaboration models for complex medical evidence synthesis.

  Full Summary

• Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

  Mohty R, Narra R, Mims A, Hunter C, Shallis R, Kota V, Jamy O, Coltoff A, Othman T, Jonas B, Patel A, DuVall A, Foucar C, Abdelsamia M, Palmisiano N, Patel S, Curran E, Omer Z, Advani A, Atallah E, Litzow M, Badar T. Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia & Lymphoma 2026, 67: 1587-1594. PMID: 41954351, DOI: 10.1080/10428194.2026.2650679.

  Peer-Reviewed Original Research

  This study investigates predictors of complete molecular response (CMR) and shows that early CMR improves relapse-free survival in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.

  Full Summary

• Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

  Berton G, Bewersdorf J, Gilhodes J, Iat A, Soua A, DeAngelo D, Boussi L, Shallis R, Žučenka A, Bystrom R, Ling K, Aguirre L, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Mendez L, Podoltsev N, Tauveron-Jalenques U, Lanino L, Stein E, Zeidan A, Forcade E, Cluzeau T, Dumas P, Heiblig M, Devillier R, Shimony S, Goldberg A, Stahl M, Garciaz S. Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia. Haematologica 2026 PMID: 41924924, DOI: 10.3324/haematol.2025.300202.

  Peer-Reviewed Original Research

  Altmetric

• CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

  Komrokji R, Komrokji Z, Al Ali N, Xie Z, Chan O, Kuykendall A, Walker A, Yun S, Reynolds S, Shallis R, Lancet J, Sallman D, Padron E. CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML? Blood Neoplasia 2026, 3: 100224. PMID: 42232990, PMCID: PMC13223902, DOI: 10.1016/j.bneo.2026.100224.

  Peer-Reviewed Original Research

  Altmetric